Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.59 |
| ▸ | PI4KA | P42356 | 11/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 11/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 11/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.54 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | AHCY | P23526 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385843 | 0.81 | ADORA2A (0.55) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23834271 | 0.81 | ADORA2A (0.58) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL3922476 | 0.80 | ADORA2A (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1272854 | 0.79 | ADORA2A (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL4298072 | 0.78 | ADORA2A (0.56) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5663802 | 0.78 | ADORA2A (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL14125909 | 0.78 | ADORA2A (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL2698569 | 0.77 | ADORA2A (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28406876 | 0.77 | ADORA2A (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1251787 | 0.76 | CDK1 (0.56) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998001459-A1 | NOVEL N-ALKOXYADENINE DERIVATIVES ACTING AS CYTOKINE INHIBITORS | NOVO NORDISK A/S (DK) | 1998-01-15 | — | — | WO | claimed |
| EP-0672171-A1 | FORMATION OF TRIPLE HELIX COMPLEXES OF DOUBLE STRANDED DNA USING NUCLEOSIDE OLIGOMERS WHICH COMPRISE PURINE BASE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-09-20 | — | — | EP | claimed |
| WO-1993005180-A1 | FORMATION OF TRIPLE HELIX COMPLEXES OF DOUBLE STRANDED DNA USING NUCLEOSIDE OLIGOMERS WHICH COMPRISE PURINE BASE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 1993-03-18 | — | — | WO | claimed |
| CN-106543182-A | The synthetic method of 4,5 dimethoxy purine of medical body, 6 amine | 无锡乾浩生物医药有限公司 | 2017-03-29 | — | — | CN | disclosed |
| US-8058032-B2 | Method for amplifying unknown DNA sequence adjacent to known sequence | SEEGENE, INC. (KR) | 2011-11-15 | — | — | US | disclosed |
| US-20070172824-A1 | Method for amplifying unknown dna sequence adjacent to known sequence | SEEGENE, INC (KR) | 2007-07-26 | — | — | US | disclosed |
| US-20050043268-A1 | Inhibition of viruses | MEDICAL RESEARCH COUNCIL (GB) | 2005-02-24 | — | — | US | disclosed |
| WO-1998001459-A1 | NOVEL N-ALKOXYADENINE DERIVATIVES ACTING AS CYTOKINE INHIBITORS | NOVO NORDISK A/S (DK) | 1998-01-15 | — | — | WO | disclosed |
| WO-1993005176-A1 | IMPROVEMENTS IN OLIGONUCLEOTIDE PRIMERS AND PROBES | MEDICAL RESEARCH COUNCIL (GB) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043268-A1 | Inhibition of viruses | RNASE1, HNRNPA1, RNASEH1 | ADORA2A 282/4885ADORA1 237/4885PI4KA 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.